INM Stock Analysis: Buy, Sell, or Hold?
INM - InMed Pharmaceuticals Inc. Common Shares
$1.43
-0.03 (-2.05%)
▼
5d:
-2.05%
30d:
-16.37%
90d:
-16.86%
HOLD
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Sep 28, 2026
Get Alerted When INM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INM is currently trading at $1.43, which is considered slightly low relative to its 30-day fair value range of $1.42 to $1.63.
Technical Outlook: Technically, INM is in a strong uptrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INM scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $20.00 (+1298.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INM is in a strong uptrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INM scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $20.00 (+1298.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.42 -
$1.63
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1298.6% below Wall St target ($20.00)
- CAUTION: Bottoming setup, but lagging the sector by 12% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.42 -
$1.63
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.40
Resistance Level
$1.65
Current Trend
Strong Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Wall Street Target
$20.00
(+1298.6%)
Revenue Growth (YoY)
-26.2%
Profit Margin
-172.2%
Share & Embed Analysis
Last updated: August 24, 2026 6:03 PM ET
Data refreshes hourly during market hours. Next update: 7:03 PM
Data refreshes hourly during market hours. Next update: 7:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
